Literature DB >> 10485464

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

J D Allen1, R F Brinkhuis, J Wijnholds, A H Schinkel.   

Abstract

Mouse fibroblast cell lines lacking functional Mdr1a, Mdr1b, and Mrp1 genes were selected for resistance to topotecan, mitoxantrone, or doxorubicin. Each of the resulting drug-resistant lines showed marked gene amplification of Bcrp1, the mouse homologue of the human ATP-binding cassette transporter gene BCRP/MXR/ABCP, and greatly elevated expression of Bcrp1 mRNA. All three of the resistant cell lines were highly cross-resistant to topotecan and mitoxantrone and, to a variable extent, doxorubicin. All showed greatly reduced cellular accumulation and greatly increased efflux of mitoxantrone that was dependent on cellular ATP and efficiently reversed by the compound GF120918. The mouse Bcrp1 cDNA encodes a 657-amino-acid protein with 81% identity (86% similarity) to the human breast cancer resistance protein (BCRP) and a virtually superimposable hydrophobicity profile. Our data argue strongly that mouse Bcrp1 is functionally comparable with human BCRP, conferring multidrug resistance to topotecan, mitoxantrone, doxorubicin, and related compounds. Mouse models and cell lines should, therefore, be highly informative in understanding the clinical, pharmacological, and physiological roles of BCRP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  72 in total

1.  Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1.

Authors:  Koichi Shimano; Makoto Satake; Atsuhito Okaya; Junichi Kitanaka; Nobue Kitanaka; Motohiko Takemura; Masafumi Sakagami; Nobuyuki Terada; Tohru Tsujimura
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

2.  Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.

Authors:  Eyob D Adane; Zhiwei Liu; Tian-Xiang Xiang; Bradley D Anderson; Markos Leggas
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

Review 3.  ATP-binding cassette, subfamily G (ABCG family).

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

Review 4.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

Review 5.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 6.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  The role of half-transporters in multidrug resistance.

Authors:  S E Bates; R Robey; K Miyake; K Rao; D D Ross; T Litman
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

8.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.

Authors:  Eran E Bram; Michal Stark; Shachar Raz; Yehuda G Assaraf
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 9.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

10.  Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).

Authors:  Durga Kalyani Paturi; Deep Kwatra; Hari Krishna Ananthula; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2009-09-25       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.